LensGen Announces Funding And Patent Success
IRVINE, Calif., July 17, 2018 /PRNewswire/ — LensGen®, Inc., a private California company developing the world’s first modular, fluid-optic, curvature changing intraocular lens (IOL) is reporting significant progress in its effort to transform how presbyopia is addressed.
The Company successfully achieved a key clinical performance milestone which triggered the release of $11 million in funding as part of the Series A Financing that was announced in May 2017. Also, lead investor HOYA Group opted to invest an additional $4.4M that was an available option in the Series A financing. “We are pleased that LensGen is continuing to make outstanding progress on its clinical and business development goals,” said Akiteru Furukawa, General Manager, Hoya Corporation Business Development. “We look forward toward the achievement of the necessary steps to starting and completing the FDA trial.”
In addition, The US Patent Office has just granted LensGen two broad and comprehensive patents protecting its proprietary modular, fluid IOL technology.
“We are thrilled to share the steady progress the LensGen team is making toward our ultimate goal of bringing the Juvene™ platform to market,” said Ramgopal Rao, LensGen Founder and Chief Executive Officer.
The Company met with several of the nation’s top refractive surgeons at the American Society of Cataract and Refractive Surgery meeting this spring in Washington D.C.
“There was great enthusiasm from the surgeons in the room about the potential of Juvene™ to ultimately transform how we treat our cataract patients,” said Eric Donnenfeld M.D. founding partner of Ophthalmic Consultants of Long Island and a past President of the American Society of Cataract and Refractive Surgery. Dr. Donnenfeld is also a member of the LensGen Scientific Advisory Board….
Read more: http://www.lensgen.com.
Source: PR Newswire